Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections

Antiviral Research

Volumn 57, Issue 1-2, 2003, Pages 13-23

  Baker, Robert O ^a   Bray, Mike ^a   Huggins, John W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral; Cidofovir; Monkeypox; Orthopox; Smallpox; Variola

Indexed keywords

1 (2,4 DIFLUOROBENZYLOXY)ADENOSINE PERCHLORATE; 1 [2 HYDROXY 2 OXO 1 (4,2 DIOXAPHOSPHORINAN 5 YL)METHYL]CYTOSINE; 2',3' DIDEOXYDIDEHYDROCYTIDINE; 3 DEAZAARISTEROMYCIN; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ADENINE DERIVATIVE; ADENOSINE DERIVATIVE; ANTIVIRUS AGENT; CIDOFOVIR; CYTIDINE DERIVATIVE; CYTOSINE DERIVATIVE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; LOBUCAVIR; METISAZONE; NELFINAVIR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; SORIVUDINE; STAVUDINE; TIAZOFURIN; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; NONHUMAN; ORTHOPOXVIRUS; POXVIRUS; PRIORITY JOURNAL; SMALLPOX; SMALLPOX VIRUS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; HUMANS; MICROBIAL SENSITIVITY TESTS; MONKEYPOX VIRUS; NEUTRAL RED; ORTHOPOXVIRUS; PLAQUE ASSAY; POXVIRIDAE INFECTIONS; VARIOLA VIRUS; VERO CELLS; VIRUS REPLICATION;

ANIMALIA; COWPOX VIRUS; DNA VIRUSES; ORTHOPOXVIRUS; POXVIRIDAE; VARIOLA; VARIOLA VIRUS;

EID: 0037288073     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00196-1     Document Type: Article

References (45)

1. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:2000a;10-19.
2. Bray M., Driscoll J., Huggins J.W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res. 45:2000b;135-147.
3. Bray M., Raymond J.L., Geisbert T., Baker R.O. 3-Deazaneplanicin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 55:2002;151-159.
4. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. Arnold, The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:2000;1375-1379.
5. Cundy K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:1999;127-143.
6. De Clercq E. S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol. 36:1987;2567-2575.
7. De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus. Res. 42:1993a;1-55.
8. De Clercq E. Antivirals for the treatment of herpesvirus infections. J. Antimicrob. Chemother. 32(Suppl. A):1993b;121-132.
9. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:2001;382-397.
10. De Clercq E., Montgomery J.A. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res. 3:1983;17-24.
11. De Clercq E., Luczak M., Shugar D., Torrence P.F., Waters J.A., Witkop B. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 151:1976;487-490.
12. De Clercq E., Sakuma T., Baba M., Paulwels S.R., Balzarini I., Rosenberg I., Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8:1987;261-272.
13. Fenner, F., Henderson, D.A., Arita. I., Jezek, Z., Ladnyi, I.D., 1988. Smallpox and Its Eradication. World Health Organization, Geneva.
14. Finter N. Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. J. Gen. Virol. 5:1969;419-427.
15. Gubser C., Smith G.L. The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J. Gen. Virol. 83:2002;855-872.
16. Hitchcock M.J.M., Jaffe H.S., Martin J.C., Stagg R.J. Cidofovir a new agent with potent anti-herpesvirus activity. Antiviral Chem. Chemother. 7:1996;115-127.
17. Hoffman V.F., Skiest D.J. Therapeutic developments in cytomegalovirus retinitis. Expert Opin. Invest. Drugs. 9:2000;207-220.
18. Huggins J.W., Zhang Z.X., Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J. Infect. Dis. 179(Suppl. 1):1999;S240-S247.
19. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75:2001;1205-1210.
20. Jordan I., Briese T., Averett D.R., Lipkin W.I. Inhibition of Boma disease virus replication by ribavirin. J. Virol. 73:1999;7903-7906.
21. Kane E.M., Shuman S. Adenosine N1-oxide inhibits vaccinia virus replication by blocking translation of viral early mRNAs. J. Virol. 69:1995;6352-6358.
22. Katz E., Margalith E., Winer B. Inhibition of vaccinia virus growth by the nucleoside analogue 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxarnide (virazole, ribavirin). J. Gen. Virol. 32:1976;327-330.
23. Kesson A.M., Ferguson J.K., Rawlinson W.D., Cunningham A.L. Progressive vaccinia treated with ribavirin and immune globulin. Clin. Infect. Dis. 25:1997;911-914.
24. Khare M.D., Sharland M. Cytomegalovirus treatment options in immunocompromised patients. Expert Opin. Pharmacother. 2:2001;1247-1257.
25. Kirsi J.J., North J.A., McKernan P.A., Murray B.K., Canonico P.G., Huggins J.W., Srivastava P.C., Robins R.K. Broad-spectrum antiviral activity of 2-beta-D ribofuranosyl selenazole 4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. 24:1983;353-361.
26. Kirsi J.J., Mckernan P.A., Burns N.J., North J.A., Murray B.K., Robins R.K. Broad-spectrum synergistic antiviral activity of selenazofurin. Antimicrob. Agents Chemother. 26:1984;466-475.
27. Kwong C.D., Krauffi C.A., Shortnacy-Fowler A.T., Arnett G., Hollingshead M.G., Shannon W.M., Montgomery J.A. III, Secrist J.A. Synthesis and antiviral evaluation of analogs of adenosine-N1-oxide and 1-(benzyloxy)adenosine. Nucleosides Nucleotides. 17:1998;1409-1443.
28. 2 cells by nucleosides and nucleotides: the role of ecto-enzymes. Biochem. J. 316(Pt. 2):1996;551-557.
29. Lutwick L.I., Goozner B., Bourke E. Bioterrorism: a primer for 2002. J. Assoc. Acad. Minor. Phys. 13:2002;9-13.
30. Maag D., Castro C., Hong Z., Cameron C.E. Hepatitis C Virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276:2001;46094-46098.
31. Massung R.F., Liu L.I., Qi J., Knight J.C., Yuran T.E., Kerlavage A.R., Parsons J.M., Venter J.C., Esposito J.J. Analysis of the complete genome of smallpox variola major virus strain Bangladesh - 1975. Virology. 201:1994;215-240.
32. Mathew T. Comparative studies on buffalo pox, vaccinia and cow pox viruses in hamster kidney cell cultures. Acta Virol. 14:1970;513.
33. Montgomery J.A., Clayton S.J., Thomas H.J., Shannon W.M., Arnett G., Bodner A.J., Kion I.K., Cantoni G.L., Chiang P.K. Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target. J. Med. Chem. 25:1982;626-629.
34. Neyts J., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:1993;242-246.
35. Noble S., Goa K.L. Adefovir dipivoxil. Drugs. 58:1999;479-489.
36. Pancheva S.N. Potentiating effect of ribavirin on the anti-herpes activity of acyclovir. Antiviral Res. 16:1991;151-161.
37. Rankin I.T. Jr., Eppes S.B., Antczak J.B., Joiklik W.K. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology. 168:1989;147-158.
38. Salmon-Ceron D. Cytomegalovirus infection: the point in 2001. HIV Med. 2:2001;255-259.
39. Sheek M.R., Chapman A.L., Wenner H.A. Human and primate poxviruses: I. Growth characteristics of cytolytic and tumor variants. Arch. Virol. 48:1975;47-61.
40. Shishkov S., Pancheva S. The synergistic antiviral effect of acyclovir and ribavirin against the herpes simplex type-1 virus and the pseudorabies virus in vitro. Acta Microbiol. Bulg. 25:1990;69-75.
41. Smee D.F., Bailey K.W., Sidwell R.W. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antiviral Chem. Chemother. 11:2000a;303-309.
42. Smee D.F., Bailey K.W., Wong M., Sidwell R.W. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 47:2000b;171-177.
43. Smee D.F., Bailey K.W., Wong M., Sidwell R.W. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52:2001;55-62.
44. Smee D.F., Sidwell R.W., Kefauver D., Bray M., Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox cowpox monkeypox and vaccinia viruses. Antimicrob. Agents Chemother. 46:2002;1329-1335.
45. Tignor G.H., Kende M., Hanham C.A. Chemotherapeutic prevention of complications caused by vaccinia virus-vectored immunogen. Ann. N.Y. Acad. Sci. U.S.A. 653:1992;334-343.